The partnership leverages Psyence’s expertise in fungi cultivation and palliative care as well as Filament’s expertise in the manufacture of pharmaceutical grade drug candidates VANCOUVER, BC, April 19, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc (CSE…


Previous articlePT313 – Christine Calvert, LCDC – Holotropic Breathwork, Ethics, and Dying To Ourselves
Next articlePsychedelics Today Has Hit 3 Million Downloads!